JAK2 associated myeloprofilerative Neoplasms
Conditions
Interventions
Group 1: Recruitment and blood collection of patients with JAK2-associated myeloproliferative neoplasms and healthy volunteers. Molecular, genetic, and cellular characterization of plasmacytoid dendri
Sponsors
Genzentrum der LMU
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Inclusion criteria
Inclusion criteria: Eligible participants include adult patients with a diagnosed myeloproliferative neoplasm (MPN) and a confirmed somatic JAK2 gain-of-function mutation, for example the V617F mutation, who are capable of providing informed consent. Samples will preferably be obtained in the context of routinely performed therapeutic phlebotomies. If no phlebotomy is scheduled, an alternative venous blood draw of up to 100 mL may be performed, provided that this is considered compatible with the patient’s health status by the treating physician. This upper limit is based on international recommendations, including the WHO Guidelines on Drawing Blood (2010). In addition, healthy adult, non-pregnant control individuals will be recruited who, after appropriate information and written informed consent, agree to a single blood draw of approximately 50 mL.
Exclusion criteria
Exclusion criteria: Excluded from participation are minors and individuals who are not capable of providing informed consent, patients with additional hematologic or solid malignancies (other than MPN), individuals with acute infections at the time of sample collection, and individuals receiving immunosuppressive medication (with the exception of PEG-interferon). Pregnancy and breastfeeding are also exclusion criteria.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Understanding the ontogeny of plasmacytoid dendritic cells | — |
Secondary
| Measure | Time frame |
|---|---|
| Clarification of the impact of PEG-Interferon Therapy on the function of pDCs | — |
Countries
Germany
Contacts
Public ContactJonathan Bohlen
Genzentrum der LMU
Outcome results
None listed